Related Experiment Video
Updated: Aug 7, 2025
06:01
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
14.9K
Thrombolysis for acute ischaemic stroke: current status and future perspectives.
Georgios Tsivgoulis1, Aristeidis H Katsanos2, Else Charlotte Sandset3
1Second Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece; Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA.
The Lancet. Neurology
|March 12, 2023
Summary
New thrombolytic agents like tenecteplase show promise for acute ischemic stroke treatment, offering improved efficacy and administration over alteplase. Research also explores adjunct therapies and advanced delivery methods to enhance reperfusion and patient outcomes.
Area of Science:
- Neurology
- Pharmacology
- Cardiovascular Medicine
Background:
- Alteplase is the sole approved thrombolytic for acute ischemic stroke.
- There is a growing need for thrombolytic agents with better safety, efficacy, and delivery.
- Tenecteplase is a potential alternative with advantages in administration and efficacy for large vessel occlusion.
Purpose of the Study:
- To review the development of novel thrombolytic agents for acute ischemic stroke.
- To discuss advancements in adjunct therapies and treatment strategies to improve reperfusion.
- To highlight the role of mobile stroke units and advanced neuroimaging in optimizing thrombolysis delivery.
Main Methods:
- Literature review of current and emerging thrombolytic therapies.
- Analysis of research on adjunct treatments and strategies to prevent reocclusion.
- Evaluation of the impact of mobile stroke units and advanced neuroimaging.
Main Results:
- Tenecteplase shows potential as a preferred alternative to alteplase.
- Adjunct therapies and new strategies aim to improve recanalization and reduce reocclusion.
- Mobile stroke units and advanced imaging can shorten treatment times and identify eligible patients.
Conclusions:
- Continued research into novel thrombolytics and delivery methods is crucial.
- Improving reperfusion and reducing reocclusion are key goals in acute ischemic stroke management.
- Enhanced stroke care infrastructure, including mobile units and advanced imaging, will facilitate better patient outcomes.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
14
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
14
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
19
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
19
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
802
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
802
01:16Clot Retraction and Fibrinolysis
6.6K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.6K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
575
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
575